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Myocardial regeneration can be induced with the im-
plantation of a variety of myogenic and angiogenic cell
types. More than 150 patients have been treated with
cellular cardiomyoplasty worldwide, 18 patients have
been treated by our group. Cellular cardiomyoplasty
seems to reduce the size and fibrosis of infarct scars, limit
postischemic remodelling, and restore regional myocar-
dial contractility. Techniques for skeletal myoblasts cul-
ture and ex vivo expansion using autologous patient
serum (obtained from plasmapheresis) have been devel-
oped by our group. In this article we propose (1) a total
autologous cell culture technique and procedures for cell
delivery and (2) a clinical trial with appropriate end-
points structured to determine the efficacy of cellular
cardiomyoplasty.
(Ann Thorac Surg 2004;77:1121–30)
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Cellular cardiomyoplasty (CMP) consists of in situ cellimplantation intended to induce the growth of new
muscle fibers and the development of angiogenesis in the
damaged myocardium. This potentially may contribute
to improve systolic and diastolic ventricular functions,
and to reverse the postischemic remodeling process
[1–3]. Adult myocardium is unable to effectively repair
after infarction due to the lack of stem cells [4–6]. For this
reason cell transplantation strategies for heart failure
have been designed to replace damaged cells with cells
that can perform cardiac work, either in ischemic or
idiopathic cardiomyopathies. Current possibilities in
myogenic and angiogenic cell therapy for myocardial
regeneration are the transplantation into the myocar-
dium of different types of cells as autologous myoblasts
(originating from skeletal muscle), bone marrow-derived
mesenchymal stem cells, circulating blood-derived pro-
genitor cells, smooth muscle cells, vascular endothelial
cells, and embryonic stem cells.
Our 15-year clinical experience with latissimus dorsi
dynamic cardiomyoplasty [1, 7] and 6-year work in ex-
perimental cellular cardiomyoplasty [1, 3, 8] provide the
support for the indication and management of cardiac-
bioassist techniques. The aim of this article is to review
the role of cell-based myogenic and angiogenic therapy
in myocardial diseases and to present an approach for
cell culture and cell delivery. In addition criteria for a
structured clinical trial determining the efficacy of cellu-
lar cardiomyoplasty are presented.
Cell Selection
One of the major questions remaining concerning cellu-
lar therapy for heart failure is which cell type is appro-
priate for myocardial regeneration?. The following list
describes the major cell types for cardiac myogenesis and
angiogenesis which have been experimentally demon-
strated to consent successful ex vivo cell-culture or cell-
selection procedures followed by intramyocardial im-
plantation (Table 1).
Myoblasts
Skeletal muscle cells are able to regenerate after injury
because of the presence of satellite cells. In postnatal
skeletal muscle, precursors (myoblasts) can be derived
from satellite cells (reserve cells located on the surface of
mature myofibers) or from cells lying beyond the myofi-
ber, eg, interstitial connective tissue or bone marrow.
Both of these classes of cells may have stem cell proper-
ties. When activated by appropriate stimuli satellite cells,
proliferate and differentiate into myotubes becoming in
some cases new muscle fibers [2, 3, 9]. The major advan-
tages of this cell type is that myoblasts are highly resis-
tant to ischemia and multiply after injury, presenting a
high power for multiple mitosis [10].
When skeletal myoblasts are used for cellular cardio-
myoplasty the sequence of actions appears to be the
following: cells transplanted into the myocardium first
impact on diastolic dysfunction. Subsequently when suf-
ficiently organized in myotubes and myofibers systolic
performance improves. Implanted cells orient them-
selves against cardiac stress preventing thinning and
dilatation of the injured region [9, 11]. However it is not
certain whether improvement in left ventricular perfor-
mance is mediated by increased systolic function caused
by synchronus contraction of the graft, since skeletal
myoblasts are known not to contract spontaneously.
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Moreover denervated skeletal myoblasts could progres-
sively become atrophic.
Bone Marrow Cells
There are four cell lineages that can be isolated from
bone marrow: hematopoietic stem cells, mesenchymal
stem cells [12], multipotent adult progenitor cells [13, 14],
and progenitor endothelial cells [15]. The mesenchymal
stem cells (called also bone marrow stromal cells) are
capable of giving rise to multiple cell lines.
The main problem remaining with bone marrow cells
is that they may differentiate into fibroblasts after im-
plantation in a fibrotic scar, with the risk of becoming a
“scar within a scar.” Thus the importance of the implan-
tation microenvironment. The apparent transdifferentia-
tion of stem cells may be due to mere cell fusion with
parenchymal cells, endowing the stem cell with special-
ized function [16].
Experimentally bone marrow stromal cells can be in-
duced to differentiate in vitro into myocytes before trans-
plant using a coculture system with cardiomyocytes [17,
18] or by including 5-azacytidine in the cultures [19]. This
approach can be compromised for clinical trials in terms
of potential cell mutations by 5-azacytidine. In vitro
electrostimulation of cell cultures is experimentally used
by our group for predifferenciation of stem cells in a
myogenic lineage [20].
Peripheral blood stem cells are similar to those ob-
tained from bone marrow aspiration. These cells can be
previously mobilized from bone marrow by administra-
tion of cytokines in the form of stimulating growth
factors, for example granulocyte-colony stimulating fac-
tor. Statins can also be used for cell mobilization [21]. The
maximum mobilization effect occurs on the fifth day of
administration, afterwards a mononuclear cell-rich frac-
tion is isolated. Side effects during cell mobilization
should be carefully evaluated, for example leucocytosis
and increase of platelet number (responsible of coagula-
tion abnormalities), splenomegaly.
Smooth Muscle Cells
Smooth muscle cells can be obtained from a segment of
artery, the vermiform appendix or the uterus during
laparoscopy. Experimental studies have demonstrated
successful in vitro cell expansion. After implantation in
pathologic myocardium, smooth muscle cells proliferate
and hypertrophy in response to the stress of cardiac
contractions. Cell engraftment has been demonstrated
to be related to the recovery of myocardial elasticity
and reduction of fibrotic tissue, improved determinants
of diastolic function have been observed [22]. These
cells do not contract spontaneously after myocardial
implantation.
Cardiomyocytes
Fetal and neonatal cardiomyocytes have been success-
fully grafted into the myocardium after in vitro expan-
sion. The presence of intercalated disks and connexin 43,
a marker of gap junctions required for cell to cell electri-
cal coupling, has been experimentally demonstrated
within grafted cardiomyocytes and between grafted cells
and host myocytes resulting in improved systolic and
diastolic ventricular function. In addition to availability,
the clinical application of fetal and neonatal cells raises
immunologic and ethical questions [23].
Adult cardiomyocytes present several drawbacks for
use in myocardial regeneration owing to the difficulty to
expand in the culture medium. In fact adult cardiomyo-
cytes do not divide as they are terminally differentiated
cells [24]. Furthermore cardiac cells require adequate
vascular supply to survive in infarcted areas, in contrast
to skeletal myoblasts which can tolerate an ischemic
environment.
Endothelial Cells
Vascular endothelial cells can be harvested from the
intima of autologous arteries or veins and be used to
induce angiogenesis and neovascularization [25]. Ex-vivo
expanded mature endothelial cells had been experimen-
tally transplanted in ischemic myocardium and limbs,
this approach presents the advantage of initiate and
promote angiogenesis without the limitations of the re-
lease of a single protein (vascular endothelial growth
factor, basic fibroblast growth factor). Endothelial cells
induce an extensive capillary network, but they might not
induce the formation of sufficient conduit vessels to
regenerate postinfarction myocardial scars. The succe-
sive association of angiogenic and myogenic cell therapy
should be beneficial, since prevascularization of myocar-
dial scars may improve local conditions for myogenic cell
survival (preconditioning).
Embryonic Cells
Embryonic stem cells can be isolated only from the inner
cell mass of blastocysts (on day 6 of development), as the
external cell mass of blastocyst will become the placenta.
These cells are characterized by their capacity to prolif-
erate in an undifferentiated state for a prolonged period
in culture. Afterward they can differentiate into every
tissue type in the body, forming derivatives of all three
germ layers: ecto, meso, and endoderm. Unfortunately
their clinical application raises immunologic barriers and
bioethical dilemmas [26] and risks of teratoma formation
Table 1. Cellular Cardiomyoplasty
Cells for cardiac myogenesis
Skeletal myoblasts
Smooth muscle cells
Bone marrow multipotent adult progenitor cells (MAPC)
Fetal and neonatal cardiomyocytes
Cells for cardiac angiogenesis
Endothelial cells (collected from the intima of arteries or
veins)
Bone marrow-derived stem cells
Circulating blood-derived progenitor cells
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because it is difficult to control the cell differentiation
process.
Cell Lines
Cell lines derived from different cell types (stem cells,
endothelial cells, and so forth) are commercially pro-
duced by cellular biology laboratories. The main draw-
back of immortalized cultured myogenic or angiogenic
cell lines is the potential for tumorogenesis. Unless
resolved this will limit the clinical application of this
approach.
Atrial Cardiomyocytes as Cardiac Pacemaker
The implantation of cultivated fetal atrial cardiomyocytes
into the ventricular wall have been proposed as a biolog-
ical cardiac pacemaker. Cardiomyocytes with a higher
intrinsic rhythmic rate can be implanted into the left
ventricle becoming an ectopic pacemaker by functional
coupling with host cardiomyocytes. Experimentally dis-
sociated fetal atrial cardiomyocytes (including sinus
nodal cells) have been implanted in the left ventricle.
Histologic studies showed survival of grafted cells, for-
mation of gap junctions between donor and recipient
cells, and spontaneous generation of electrical signals
having the morphology of QRS complexes of escape
rhythm [27]. This approach may open a new perspective
for the treatment of cardiac arrhythmia, principally for
infants and premature babies with congenital atrioven-
tricular block.
Mechanisms of Beneficial Effects
The main mechanisms involved determining the benefi-
cial effects of cellular cardiomyoplasty appear to be:
reduction of size and fibrosis of infarct scars, limitation of
postischemic ventricular remodeling, improvement of
left ventricular wall thickening and compliance (diastolic
pressure-strain relationship), and increase in regional
myocardial contractility (Table 2) [3, 6, 22, 24, 28, 29]. The
mechanism explaining the transmission and propagation
of electrical impulses from the native myocardium to the
engrafted cells has not been elucidated. Response to a
mechanical stimulus exerted by surrounding cardiomy-
ocytes could be responsible for inducing this contraction.
Thus functional improvement is obtained from a combi-
nation of factors. Beneficial effect of cellular CMP is also
based on the regeneration of the collagen matrix [30].
During the cell culture process approximately 20% of
fibroblasts remain in mixture with myoblasts. After im-
plantation these fibroblasts could contribute to the re-
generation of the myocardial collagen matrix. In order to
elucidate the effects of cellular CMP a recent study was
performed using a computerized finite element model,
with simulations of myocyte transplantation in a failing
left ventricle [31].
Patient Selection
ISCHEMIC CARDIOMYOPATHY INCLUSION CRITERIA. Clinical ap-
plication for cell transplantation is indicated in patients
presenting a myocardial infarction of mild extension
(between 12 and 18 cm2, representing approximately one
third of the left ventricle area), without extensive involve-
ment of the ventricular septum (since this portion of the
heart is not easily approachable by cell injection). Early
cell injection after infarction should be beneficial to
prevent a large fibrotic scar. However it appears reason-
able to inject cells only after the postischemic inflamma-
tory reaction has subsided [32].
Patients preimplantation clinical status for cellular
CMP should be the following: New York Heart Associa-
tion functional class 2 or 3 or equivalent symptoms, with
or without angina; left ventricular wall thickness at echo-
cardiographic evaluation of 4 mm or greater in order to
avoid extramyocardial injection and the risk of secondary
left ventricle rupture due to the multiple injection points;
left ventricular ejection fraction between 20% and 40%.
ISCHEMIC CARDIOMYOPATHY EXCLUSION CRITERIA. All patients
with skeletal muscle diseases should be excluded for
myoblast implantation. Patients having a history of sus-
tained ventricular tachycardia or fibrillation as well as
patients with implantable cardiac defibrillators (ICD) or
potential candidates for ICD implantation should be
carefully evaluated, as transplant cell-induced arrhyth-
mias are a potential complication. Furthermore subjects
with an history of syncope during the previous year,
cancer within 5 years, or with an active infectious disease
or with positive tests to viral disease should be excluded.
IDIOPATHIC DILATED CARDIOMYOPATHY. Nonischemic cardio-
myopathy could benefy from cellular CMP. Cell trans-
plantation have been successfuly performed in small
cardiomyopathic animals [23], in a canine model of
idiopathic dilated cardiomyopathy [15], and in doxorubi-
cin-induced heart failure [33]. On the basis of these
experimental results cellular CMP may improve heart
function in patients with nonischemic cardiomyopathy.
The grafted cells appear to better survive in the host
myocardium because myocardial irrigation in this pa-
thology is not significantly impaired.
Table 2. Cellular Cardiomyoplasty: Mechanisms of Beneficial
Effects
Ventricular remodeling
Reduces the size and fibrosis of infarct scars
Minimizes global ventricular dilatation
Increases myocardial wall thickness
Induces modulation of extracellular matrix remodeling
Diastolic function
Improves myocardial wall tension and elasticity
Improves of strain and dynamic stiffness
Reverses diastolic creep
Systolic function
Improves regional ventricular wall motion
Increases developed pressures
Improves global ventricular contraction?
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MUSCLE BIOPSY AND CELL CULTURE TECHNIQUES. To initiate ex-
vivo cell culture procedures, the following “virus free
tests” should be performed: antihuman immunodefi-
ciency virus (HIV), antihepatitis B-C virus (HBV, HCV),
immunoglobulin (Ig) M anticytomegalovirus (CMV),
HbsAG, and human T-cell leukemievirus.
The following is a description of the technique used by
our group to perform myogenic cellular CMP (Table 3).
Skeletal Muscle Biopsy
Three weeks before cellular CMP, a biopsy sample of the
thigh vastus lateralis is taken through a 5-cm incision
under local anesthesia. Local anesthetic agents appears
to stimulate dormant myogenic cells. A 2- to 3-cm3
skeletal muscle sample (12 to 18 g) is explanted under
sterile conditions (Fig 1). Immediate fragmentation of the
muscle with scissors is performed and then immerged in
complete culture medium or in PBS (phosphate buffer
solution, GIBCO, Rockville, MD) and kept at 4°C. The
procedure for cell isolation and culture should start as
soon as possible so as to guarantee maximun cell sur-
vival. However samples can be stored in an appropriate
container at low temperature and secondarily trans-
ported to the laboratory.
Cell Isolation and In Vitro Expansion
All manipulations should be performed in a laminar flow
hood using an aseptic technique. The explanted skeletal
muscle pieces are washed in PBS. Adipose tissue and
fascia are removed and the muscle is carefully minced
with scissors. The muscle fragments are washed again in
PBS until the supernatant remains clear. Centrifugation
is carried out at 100g for 5 minutes. Tissue dissociation is
obtained by two consecutive enzymatic treatments: first,
cells are incubated with collagenase IA (1.5 mg/mL for
each gram of tissue; Sigma Chemical) and left in the
incubator for 1 hour, followed by mechanical dissociation
obtained by shaking the tube every 10 minutes. Alterna-
tively, the tube can be placed in a 37°C reciprocating/
orbital shaking incubator (ROSI, Thermolyne, Dubuque,
IO). A second incubation with 0,25% trypsin 1x ethyl-
enediamine tetraacetic acid (EDTA [2 mL, GIBCO BRL])
is then performed for 20 minutes. Cells are then washed
(10 minutes at 300g) and enzymatic reaction stopped by
adding 1 mL of the patients own serum. Filtration
through a 40- sieve (cell strainer nylon, Falcon, Becton
Dickinson, Franklin Lakes, NJ) is then performed and a
second enzymatic digestion is conducted on the remain-
ing fragments which eventually rest on the sieve. Cells
are collected by sedimentation (20 minutes at 300g) and
the supernatant is discarded.
Cells pellets are resuspended in fresh complete culture
medium: 79% HAM-F12 medium, 20% patient’s serum
(obtained from blood sample or from plasmapheresis),
1% penicillin/streptomycin (GIBCO) and plated in tissue
culture flasks of 300 cm2 (TPP, Trasadingen, Switzerland).
Amphotericin B (0.25 g/mL) and 25 pg/mL basic fibro-
blast growth factor (human recombinant, Sigma) can be
included in the culture medium. Afterwards cell cultures
are incubated during 3 weeks at 37°C in a humidified
atmosphere containing 5% CO2. Flasks should be posi-
tioned without tilt in the incubator in order to avoid
irregular cell proliferation. After a 2- to 3-day incubation
time, the medium is changed eliminating dead and blood
cells in the supernatant, then fresh complete culture
medium is added. Passaging of the cultures (1:5 split) is
carried out at subconfluency (50% of confluency) to avoid
the occurance of myogenic differentiation at higher den-
sities. Frequent passaging at 50% confluence is required
to prevent the mononucleated cells from differentiating
into myotubes. The mean volume of patients’ autologous
serum prepared for myoblast cultures is 1500 mL. Ali-
quots of 50 mL are cryopreserved until usage.
Table 3. Guidelines for Myoblast Culture Technique
All manipulations should be carried out in a laminar flow
hood using aseptic technique
Removal of fibrous and adipose tissue from muscle biopsy
Muscle mincing with scissors
Enzymatic (collagenase  trypsin) and mechanical digestion
Multiple centrifugations
Isolation of myoblasts, exclusion of fibroblasts
In vitro myoblasts culture: incubation during 3 weeks in
humidified atmosphere, at 37°C, 5% CO2
Assessment of percent cell viability (Trypan blue or flow
cytometry)
Assessment of myoblasts/fibroblasts rate (CD56-positive and
desmin antibodies)
Sterility tests: bacterial, viral, fungal
Cell suspension in 0.5% human albumin for myocardial
injection
Fig 1. A 2 to 3 cm3 biopsy sample of the thigh vastus lateralis (12
to 18 g) is explanted under local anesthesia and high sterile
conditions.
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Cell culture flasks are periodically observed using an
inverted light microscope with fluorescence (Nikon
Eclipse TE 300, Melville, NY). When subconfluency is
obtained a first passage is performed. Cells are harvested
by trypsinization (2 mL 0.25% trypsin-EDTA in each flask
for 1 to 5 minutes in the incubator). Complete cell
detachment is demonstrated by observing floating cells
under microscopy. The reaction is then stopped with
complete culture medium and the resultant cell suspen-
sion is split into another five flasks. Additional passages
should be performed in order to obtain the final cells
quantity. Commonly, after 3 weeks, more then 200  106
cells are obtained (Fig 2). The cell number can be scaled
up by repeated passaging in a multiple-tray cell factory
or using rotary cell culture systems (Synthecon, Houston,
TX). Bacterial (aerobic and anaerobic tests), viral, and
fungal controls should be performed at each step of the
cell culture procedure.
Fibroblast Removal From Myoblast Culture
In order to reduce the number of fibroblasts and achieve
a pure myoblast culture, a preplating step is applied on
the first passage. Preplating technique is based on the
quicker attachment of fibroblasts compared with satellite
cells. Samples in which myoblast purity is below 30% are
Fig 2. Human skeletal myoblasts after a 3-week in vitro culture pe-
riod (magnification 40).
Fig 3. Quantification of myoblasts by flow cytometry. Muscle progenitor cells were harvested and labeled with mouse antihuman CD56 (before
preplating step and after 3 weeks in culture). Alternatively cells were labeled with a mouse antibody against human desmin. Isotype antibodies
were used as negative controls.
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subjected to a positive CD56 cell selection using micro-
magnetic immunobeads (Anti-Fibroblast MicroBeads;
Miltenyi Biotec, Bergisch-Gladbach, Germany). After this
selection myoblast purity is generally greater than 90%.
The magnetic technique for removing fibroblasts consists
in the use of antibodies recognizing muscle progenitor
specific cell surface antigens.
Injection Medium
On the day of transplantation, cells are harvested and
washed in the injection medium (human albumin 0.5%
plus complete culture medium) and kept in ice before
implantation. A sample is performed to assess final
myoblast rate, by flow cytometry test: percentage of
myoblasts CD56-positive (Miltenyi Biotec), and desmin
antibody positive cells (Sigma-Aldrich, France; Fig 3).
Cell concentration and viability are determined with
Trypan blue using a Malassez cytometer or FACS (flow
cytometry). Sterility of cell culture is also assessed before
implantation (Gram tests).
Cell Implantation
Cellular implantation can be performed by an epicardial
or an endovascular delivery approach. In the surgical
approach (conventional or minithoracotomy/sternotomy)
the ischemic area is well exposed permitting approxi-
mately 10 injections of the cell suspention with a 24G to
26G curved needle (for example 25G  40 mm retrobul-
bar ophthalmic needle). The use of a long needle avoids
multiple traumatic injection points.
Recommended density of implanted cells is between
50 to 70 million cells per mL. The cell injection procedure
should be performed slowly, taking approximately 15
minutes. Cells should be delivered when the implanted
needle is progressively removed from the myocardium.
The needle injection sites needs finger compression (1 to
2 minutes) after every injection, in order to avoid regur-
gitation of the cell solution (channel leakage). The num-
ber of injection points depends both on the size and
configuration of the myocardial infarcted area. Our ap-
proach consists in performing the main implantation in
the peri-infarct area (70% of cells), since residual irriga-
tion and collateral myocardial revascularization in this
intermediate area allows for a better survival of the
implanted cells. The remaining 30% of cells are im-
planted in the central portion of the scar. The effects of
this cell implantation procedure will be the centripetal
reduction of the infarct area. For idiopathic dilated car-
diomyopathies, multiple cell injections between the cor-
onary artery branches should be performed in both
ventricles.
Catheter-Based Cell Implantation
INTRACORONARY. The intravascular delivery is based on the
potential migratory properties of some cells which retain
their ability to cross the basal lamina (Table 4). This
approach could be reserved for nonischemic cardiomy-
opathies, since intracoronary cell delivery constitutes
microemboli that could potentially decrease blood sup-
ply in ischemic patients [33–36].
ENDOVENTRICULAR. Intramyocardial cell injection can be
performed by a percutaneous transfemoral endoven-
tricular approach. Several catheters are available: Myo-
Star catheter (Johnson and Johnson, Diamond Bar, CA)
[8, 37], Myocath delivery system (Bioheart Inc, Weston,
FL) [38], Stiletto (Boston Scientific, Maple Grove, MN)
[38], and a helical catheter (Biocardia Inc, San Francisco,
CA) [39]. Magnetic resonance imaging compatible cath-
eters are also in development [39, 40].
INTRAVENOUS. Systemic intravenous cell delivery can be
performed for myocardial ischemia [41]. The disadvan-
tage of this approach is the nonselective distribution
pattern of injected cells.
Another approach consists in a percutaneous selective
coronary venous cannulation and intramyocardial cell
injection (TransAccess MicroLume Delivery System,
Transvascular, Inc, Menlo Park, CA). The coronary sinus
is cannulated percutaneously and a balloon-tipped cath-
eter advanced to the anterior interventricular vein or
middle cardiac vein. A microinfusion catheter is then
advanced through a sheathed extendable nitinol needle,
deep into remote myocardium [42].
Patient Follow-Up
Patient hospital discharge should be carefully evaluated,
as ventricular arrythmias can be observed during the first
15 postimplantation days. They are probably due to the
incorporation of cells and the culture medium into the
ventricular wall, representing a risk of ectopic generation
of electrical disorders. For this reason electrocardio-
graphic monitoring and postoperative antiarryhtmic
medication is justified (for example amiodarone). Fur-
thermore corticosteroids can be administered after cell
implantation in order to reduce the inflammatory re-
sponse due to inoculation. Our approach consisting of
cell cultures in human autologous serum demonstrated
the absence of postoperative cardiac arrhythmias.
Table 4. Cell Implantation Technologies
Epicardial approach
Surgical: conventional or minimally invasive
Thorascocopic
Endoventricular
Catheter-based cell delivery. Guidance:
Three dimensional electromechanical mapping
Biplane fluoroscopy and ultrasound guidance
Magnetic resonance imaging compatible catheter
Intravascular
Catheter-based intracoronary
Coronary venous route or intravenous systemic
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Patients are studied every 3 months during the first
year of follow-up and every 6 months thereafter. Heart
failure neurohormonal factors, for example brain natri-
uretic peptide (BNP) should be included in the follow-up.
Ventricular function is evaluated by basal-dobutamine
stress echocardiography and radionuclide ventriculogra-
phy (MIBI-gated single-position emission computed to-
mography [SPECT]). Myocardial viability is assessed
with fluorodeoxyglucose (18-FDG) positron emission to-
mography (PET), uptake of gadolinium by magnetic
resonance imaging, and stress-redistribution-reinjection
201thallium scintigraphy.
Clinical Studies
Three clinical trials on cellular CMP have been initiated
by our group.
Myoblast Trial
Autologous cultivated skeletal myoblasts have been im-
planted in postinfarction myocardial scars during coro-
nary artery bypass graft surgery. Procedures were per-
formed in 18 patients. Myoblasts were cultivated during
3 weeks in autologous patient’s serum obtained by plas-
mapheresis or from blood samples. Patients treated with
autologous-serum cultivated cells were free of cardiac
arrhythmia; this obviates the need for the implantation of
a defibrillator [8, 43].
Cells CD133
Mobilized mononuclear bone marrow cells have been
implanted into postinfarction myocardial scars during
CABG. This protocol is based in the utilization of a
subpopulation of bone marrow cells, the CD133 pro-
genitors, which have a tendency to differentiate in true
angioblasts and muscle cells. Cells are obtained from
peripheral blood after mobilization with granulocyte-
colony stimulating factor. Cell selection is performed
using a isolation kit including a magnetic separation
column (CliniMACS, Miltenyi Biotec). This approach
avoids cell culture procedures [15].
Cells for Ischemic Mitral Valve Regurgitation
The MIRAGE clinical trial (Mitral-valve Ischemic Repair
Associated with Graft of Endogenous-cells) includes ran-
domly patients presenting left ventricle postischemic
scars (akinetic and metabolically nonviable) and surgical
indication for mitral valve repair. Cells CD133 are
implanted during open-heart surgery in the posterior left
ventricle wall and the papillary muscle, using a simulta-
neous endoventricular and epicardial injection approach.
Ischemic mitral regurgitation is a distinctive valve dis-
ease in that, unlike with organic valvulopathies, abnor-
malities of the left ventricle are not the consequence but
the cause of the valve disease. Ischemic mitral regurgi-
tation is more a pathology of the myocardium than the
valve [44].
International Clinical Trials
Since June 2000 more than 150 patients with ischemic
myocardial disease and some with dilated cardiomyopa-
thy have been treated worldwide in various cellular
therapy clinical trials. The number of patients treated
with autologous skeletal myoblasts was equivalent to
those treated with bone marrow cells (BMC) and the
number of surgical implantations was equivalent to those
of percutaneous catheter-based procedures. The geo-
graphical distributions was as follows:
Europe
Clinical trials have been performed in the following
countries. France: [15, 45]. Spain: Pamplona [46],
Salamanca, Coruna, Valladolid. Germany: Dusseldorf
[35]; Rostock [47], Frankfurt [36]. United Kingdom: Leic-
ester [48]. Netherlands: Rotterdam [49]. Italy: Milan,
Padova [49]. Poland: Poznan. Russia: Tomsk.
Americas
United States: Arizona Heart Institute [50], Mount Sinai
NY Hospital, Temple University Hospital, UCLA, Cleve-
land Clinic, University of Michigan [51], Washington
Hospital Center [52]. Bioheart Inc and Genzyme Corp
announced myoblast trials to be performed in America
and Europe (MyoHeart and MAGIC Trials: Myoblast
Autologous Grafting in Ischemic Cardiomyopathy); in
these trials implantable cardioverter defibrillators should
be associated. Argentina: Avellaneda Hospital Buenos
Aires [53], Rosario, La Plata. Brazil: Incor San Pablo, Rio
de Janeiro [54].
Asia
Japan: Yamaguchi University, Ube [55]. China: Hong
Kong University [56], Nanjing Medical University [57].
Singapore: National University Hospital [58].
Comment
Cell transplantation is being recognized as a viable
strategy to improve myocardial viability and limit infarct
growth. Encouraging experimental results have permit-
ted the clinical application of cellular CMP. In our ap-
proach a total autologous myoblast culture procedure
was used. The main benefits of human-autologous-
serum cell expansion is that it can be performed without
risk of prion, viral, or zoonoses contamination. Tradi-
tional cell cultures techniques involve the use of fetal
bovine serum (FBS) for cell growth. Contact of human
cells with fetal bovine serum results after 3-week in
fixation of animal proteins on the cell surface, represent-
ing an antigenic substrate for immunologic adverse
events. After cell implantation an inflamatory reaction
occurs with subsequent fibrosis. Clinical-pathologic
studies performed after cellular CMP showed the trans-
planted cells were embedded within fibrosis and without
neovascularization [51, 59]. This histologic configuration
represents a risk for micro-reentry circuits that can in-
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duce ectopic generation of severe ventricular arrhyth-
mias. When in vitro myoblasts culture is produced using
autologous blood serum the risk of arrhythmia is reduced
[60]. This obviate the need for the implantation of defi-
brillators [8, 43, 46, 53].
The technical approach used to implant the cells could
influence the efficacy of cellular CMP. In fact cell mortal-
ity after transplantation appears to be more important
when grafted in the center of high-fibrotic ischemic scars
(decreased oxygen and nutrients supply to the chronic
ischemic myocardium) [32]. Implanting the cells mainly
in peri-infarct areas and the association with therapeutic
angiogenesis may improve cell survival and the results of
cellular CMP [2, 61]. The best functional results seems to
be obtained in patients presenting a heterogeneous in-
farct area (patchy appearance), namely a mixture of
viable myocardial tissue and multiple small scars. There-
fore a “vascularized fibrosis” seems to be a better indi-
cation for cellular CMP than a “nonvascularized” postin-
farct scar [43]. It is possible that periodically repeated cell
injections should be necessary to progressively reduce
the size of infarct scars in ischemic cardiomyopathies or
to gradually improve diseased myocardium in nonisch-
emic cardiomyopathies. This approach should be simpli-
fied by the development of percutaneous catheter-based
cell implantation procedures.
Combined cellular transplantation with multisite car-
diac pacing is actually under investigation in our depart-
ment. After skeletal myoblast implantation in a experi-
mental myocardial infarction model, atrial synchronized
biventricular pacing was performed using epicardial
electrodes. These studies showed improved cell distribu-
tion, development of myotubes and increased expression
of slow myosin heavy chain isoforms (better adapted at
performing cardiac work). In addition, this combined
approach should be promoted in patients with indication
of atrio-biventricular resynchronisation [8, 62].
Perspectives
Cell implantation to treat patients with ischemic or
dilated cardiomyopathy is a new concept. Data from
well-designed clinical studies are needed to confirm the
beneficial effects observed in feasibility studies. Directly
injecting skeletal myoblasts-derived cells into ischemic
myocardium seems to provide the substrate for electrical
instability leading to malignant arrhythmia. A number of
clinical difficulties remain to be solved, for example
concerning the choice of the best cell type and the best
cell dose for each cell type. Also the most optimal method
to improve cell engraftment after implantation remains
to be be identified. Future randomized studies should
provide convincing evidence that cellular cardiomyo-
plasty itself has any beneficial effects as most of the
studies have been performed while associating surgical
or percutaneous coronary artery revascularization
procedures.
The major challenges for future research programs are
the preconditioning for predifferentiation of stem cells
before transplantation [63, 64], the improvement of host-
cell interactions (mechanical and electrical coupling), and
the optimization of the rate of surviving cells after myo-
cardial implantation [65, 66]. The association of cell-
based therapeutic angiogenesis before cellular myogen-
esis seems to be justified in order to induce
prevascularization of postinfarct scars. Electrostimulated
cellular CMP should play an important role in transform-
ing a passive cell-based procedure to a dynamic cellular
support.
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